ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1696

A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases

Vitor Aguiar1, Marcella Franco1, Nada Abdel Aziz1, Daniela Fernandez-Salinas2, Marcos Chinas1, Mariasilvia Colantuoni2, Qian Xiao1, Nicolaj Hackert1, Yifei Liao3, Rodrigo Cervantes-Diaz1, Marc Todd1, Brian Wauford1, Alex Wactor1, Vaishali Prahalad1, Raquel Laza-Briviesca1, Roxane Darbousset1, Qiang Wang1, Scott Jenks4, Kevin Cashman4, Esther Zumaquero4, Zhu Zhu1, Junning Case3, Paloma Cejas5, Miguel Munoz-Gomez5, Hannah Ainsworth6, Miranda Marion7, Mehdi Benamar1, Pui Lee8, Lauren Henderson9, Margaret Chang2, Kevin Wei10, Henry Long5, Carl Langefeld11, Benjamin Gewurz3, Ignacio Sanz4, Jeffrey Sparks12, Esra Meidan13, Peter Nigrovic2 and Maria Gutierrez-Arcelus2, 1Boston Children's Hospital, Boston, 2Boston Children's Hospital, Boston, MA, 3Brigham and Women's Hospital, Boston, 4Emory University, Atlanta, 5Dana Farber Cancer Institute, Boston, 6Wake Forest University, Winston-Salem, NC, 7Wake Forest, Winston-Salem, 8Boston Children's Hospital, Newton, MA, 9Boston Children's Hospital, Watertown, MA, 10Brigham and Women's Hospital at Harvard Medical School, Boston, MA, 11Wake Forest University School of Medicine, Winston Salem, NC, 12Brigham and Women's Hospital, Boston, MA, 13Boston Children's Hospital, Somerville, MA

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, B-Lymphocyte, Genome Wide Association Studies, genomics, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

Session Type: Abstract Session

Session Time: 4:00PM-4:15PM

Background/Purpose: Most genetic variants that confer risk of complex autoimmune diseases affect gene regulation in specific cell types. Their target genes and focus cell types are often unknown, partially because some effects are hidden in untested cell states. B cells play important roles in autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, and multiple sclerosis. However, despite this established importance, B cell activation states are underrepresented in functional genomics studies.

Methods: In this study, we obtained B cells from 26 healthy female donors. We stimulated B cells in vitro with six activation conditions targeting key pathways: the B cell receptor (BCR), Toll-like receptor 7 (TLR7), TLR9, CD40, and a cocktail that promotes differentiation into double negative 2 (DN2) IgD– CD27– CD11c+ CD21– B cells, a likely pathogenic B cell subset for autoimmunity (Fig. 1). We profiled up to 24 human B cell activation states and up to 5 control conditions using RNA-seq, single-cell RNA-seq coupled with surface protein markers (CITE-seq), and ATAC-seq.

Results: We provide an in-depth characterization of how autoimmune disease-associated genes respond to stimuli and group into modules with distinct functions (Fig. 2a-c). Using high-depth RNA-seq data, we find pervasive splicing effects during B cell activation. Using single-cell data, we describe stimulus-dependent B cell fates (Fig. 2d-g). Chromatin data reveal the transcription factors likely involved in stimulus-dependent B cell activation. These open chromatin regions capture a significant proportion of the genetic risk of multiple autoimmune diseases and elucidate autoimmune disease genetic risk variants with previously unknown function. To validate the utility of our findings, we performed fine-mapping for an SLE risk locus and identified a candidate causal variant (Fig. 3a) that overlaps an open chromatin region specific for B cells activated with the DN2-cocktail (Fig. 3b). This intergenic open chromatin peak is 15kb away from TNFSF4, which codes for OX40L and mediates interaction with activated T cells. TNFSF4 gets upregulated with DN2-cocktail activation at 48 and 72 hours (Fig. 3c). We used CRISPR inactivation in a B cell line to silence the putative enhancer where the SLE risk variant is located, which demonstrated that its target gene is TNFSF4 (Fig. 3d). We have made our multiomics resource available via an interactive browser that can be used to query the dynamics of gene regulation and B cell differentiation during activation by different stimuli, enhancing further investigation of B cells and their role in autoimmune diseases.

Conclusion: Our B cell activation multi-omics resource reveals how B cells are transcriptionally and epigenetically wired to respond to distinct stimuli, highlighting pathway-specific activation programs. It also offers mechanistic insights into the genetic basis of autoimmune diseases, including functional validation of a lupus-associated risk locus.

Supporting image 1Figure 1. B cell activation resource. Illustration of experimental design, activation conditions used, and assays performed. Created with Biorender.

Supporting image 2Figure 2. Dynamic gene expression in activated B cells over time and pathway-dependent B cell fates. a, Principal component analysis (PCA) with the top 2,000 most variable genes shows separation of conditions and time points. Inset: PCA plot highlighting conditions that include BCR stimulation. b, Expression levels of selected B cell activation genes. c, Modules of gene expression identified by Weighted Gene Correlation Network Analysis (WGCNA). X-axis: time in hours. On the right, enrichment of Gene Ontology (GO) biological processes for modules. d, Uniform Manifold Approximation and Projection (UMAP) based on gene expression after Harmony correction. e, Proportion of B cell subsets defined by expression of marker protein/genes (genes in italic) for each condition and time point (colors as in (d)). f, UMAP as in (d) colored by protein expression levels of key markers. g, UMAP as in (d) colored by gene expression levels of autoimmunity-associated genes.

Supporting image 3Figure 3. TNFSF4/OX40L locus. (a) GWAS data from Langefeld et al.40 rs2205960 is the most likely causal variant. PIP: posterior inclusion probability from SuSiE.67 (b) Chromatin peaks at the genomic region in (a). (c) TNFSF4 gene expression in the same conditions shown in (b). TPM: transcripts per million. (d) CRISPRi shows that inhibiting the region containing the putative causal variant leads to TNFSF4 downregulation.


Disclosures: V. Aguiar: None; M. Franco: None; N. Abdel Aziz: None; D. Fernandez-Salinas: None; M. Chinas: None; M. Colantuoni: None; Q. Xiao: None; N. Hackert: None; Y. Liao: None; R. Cervantes-Diaz: None; M. Todd: None; B. Wauford: None; A. Wactor: None; V. Prahalad: None; R. Laza-Briviesca: None; R. Darbousset: None; Q. Wang: None; S. Jenks: None; K. Cashman: None; E. Zumaquero: None; Z. Zhu: None; J. Case: None; P. Cejas: None; M. Munoz-Gomez: None; H. Ainsworth: None; M. Marion: None; M. Benamar: None; P. Lee: Pfizer, 2; L. Henderson: Bristol-Myers Squibb(BMS), 5, Pfizer, 2, Sobi, 2; M. Chang: None; K. Wei: 10X Genomics, 5, anaptysbio, 2, Gilead, 5, Merck/MSD, 5, Mestag, 2, Pfizer, 2; H. Long: None; C. Langefeld: None; B. Gewurz: None; I. Sanz: None; J. Sparks: Boehringer Ingelheim, 5, Bristol-Myers Squibb (BMS), 5, Janssen, 5; E. Meidan: None; P. Nigrovic: None; M. Gutierrez-Arcelus: None.

To cite this abstract in AMA style:

Aguiar V, Franco M, Abdel Aziz N, Fernandez-Salinas D, Chinas M, Colantuoni M, Xiao Q, Hackert N, Liao Y, Cervantes-Diaz R, Todd M, Wauford B, Wactor A, Prahalad V, Laza-Briviesca R, Darbousset R, Wang Q, Jenks S, Cashman K, Zumaquero E, Zhu Z, Case J, Cejas P, Munoz-Gomez M, Ainsworth H, Marion M, Benamar M, Lee P, Henderson L, Chang M, Wei K, Long H, Langefeld C, Gewurz B, Sanz I, Sparks J, Meidan E, Nigrovic P, Gutierrez-Arcelus M. A multi-omics resource of B cell activation reveals genetic mechanisms for autoimmune diseases [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-multi-omics-resource-of-b-cell-activation-reveals-genetic-mechanisms-for-autoimmune-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-multi-omics-resource-of-b-cell-activation-reveals-genetic-mechanisms-for-autoimmune-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology